Biogen Looks To Bulk Up Rare Disease Portfolio… Topline Texas-based Reata Pharmaceuticals, which earlier this year got the first federal approval to treat…
Cell And Gene Therapies Face Persistent… Laboratory in which genes are being edited.getty The approvals in June of two gene therapies, Elevidys and…
Biogen receives FDA approval for breakthrough… Cambridge-based Biogen has gotten the green light for a breakthrough ALS treatment that targets a devastating,…
Experts Raise New Questions About The Safety Of… Cells in an Alzheimer’s affected brain, with abnormal levels of the beta-amyloid protein clumping ... together to…
House investigation faults FDA approval of… The Food and Drug Administration’s (FDA) process for approving a controversial Alzheimer’s drug with…
Congress faults US regulator’s approval of… Two US congressional committees have accused the Food and Drug Administration of inappropriately…
What You Should Know About The Anti-Alzheimer’s… an elderly woman exercising to combat Alzheimer's disease in a care center for elderly, Galicia, ... 27th November…
Experimental Alzheimer’s drug slows disease,… An experimental Alzheimer’s drug modestly slowed the brain disease’s inevitable worsening, researchers…
Gantenerumab’s Phase 3 Flop Means Lecanemab… Doctor viewing brain scans for possible disease or damage.getty In results posted today, Roche’s investigational…
Ticker: Biogen tops 3Q expectations; Amazon… Biogen delivered a better-than-expected third quarter and hiked its 2022 forecast, as cost cutting continued to…